|
Q4 FY2024
As of Oct 31, 2024
|
Q3 FY2024
As of Jul 31, 2024
|
Q2 FY2024
As of Apr 30, 2024
|
Q1 FY2024
As of Jan 31, 2024
|
Q4 FY2023
As of Oct 31, 2023
|
Q3 FY2023
As of Jul 31, 2023
|
Q2 FY2023
As of Apr 30, 2023
|
Q1 FY2023
As of Jan 31, 2023
|
Q4 FY2022
As of Oct 31, 2022
|
Q3 FY2022
As of Jul 31, 2022
|
Q2 FY2022
As of Apr 30, 2022
|
Q1 FY2022
As of Jan 31, 2022
|
Q4 FY2021
As of Oct 31, 2021
|
Q3 FY2021
As of Jul 31, 2021
|
Q1 FY2021
As of Jan 31, 2021
|
Q2 FY2021
As of Apr 30, 2021
|
Q4 FY2020
As of Oct 31, 2020
|
Q4 FY2016
As of Oct 31, 2016
|
Q3 FY2016
As of Jul 31, 2016
|
Q2 FY2016
As of Apr 30, 2016
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Fixed assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Capitalized software development costs | ||||||||||||||||||||
| Long-term investments | ||||||||||||||||||||
| Software development | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Other Assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES & STOCKHOLDERS’ DEFICIT | ||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses | ||||||||||||||||||||
| Derivative Liabilities | ||||||||||||||||||||
| Due to related party | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Gain or loss | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Convertible Notes | ||||||||||||||||||||
| Total long term liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES :- | ||||||||||||||||||||
| Preferred Stock Series A, par value $0.001, 10,000,000 shares authorized, 10,000,000 shares issued and outstanding as of October 31, 2024 and October 31, 2023, respectively | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Total preferred Stock Series A, par value $0.001, 10,000,000 shares authorized, 10,000,000 shares issued and outstanding as of October 31, 2024 and October 31, 2023, respectively | ||||||||||||||||||||
| Common stock, par value $0.0001, 950,000,000 shares authorized, 129,641,074 and 126,160,534 issued and outstanding as of October 31, 2024 and October 31, 2023, respectively | ||||||||||||||||||||
| Common stock to be issued | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| TOTAL STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
Loading...
